Clinilabs invites you to their event

Alzheimer’s Disease: Drug Development and the Changing Alzheimer’s Disease Therapeutic Landscape

About this event

Join us on Thursday, September 22, at 1 pm ET. Dr. Jeffrey Cummings will discuss drug development and the changing Alzheimer's Disease therapeutic landscape. Dr. Cummings will review in great length the following key items:

  • Candidate treatments in the drug development pipeline are directed at a wide variety of targets
  • Biomarkers play multiple key roles in Alzheimer’s Disease drug development
  • Anti-amyloid monoclonal antibodies are making progress toward approval and possible clinical implementation

Hosted by

  • Team member
    Jeanine Falinski Vice President, Strategy and Corporate Development @ Clinilabs Drug Development Corporation

    Ms. Jeanine Falinski, VP of Strategy and Corporate Development, has more than 20 years of experience in the pharmaceutical industry. Jeanine graduated from Emerson College with a degree in New Media and Marketing, later on receiving her MBA in Pharmaceutical Management from Drexel University.

  • Guest speaker
    JC G
    Jeffrey Cummings


The CRO for CNS

We are a global, full-service contract research organization (CRO), the only one focused exclusively on central nervous system (CNS) drug development. We are dedicated to bringing new therapies to patients living with mental health, neurological and substance abuse disorders.